SomaLogic, Inc. (SLGCW)
| Previous Close | 4.6400 |
| Open | 4.0000 |
| Bid | 3.8700 x 1000 |
| Ask | 3.9900 x 900 |
| Day's Range | 3.9600 - 4.0000 |
| 52 Week Range | 3.9600 - 4.0000 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
SomaLogic Reports Third Quarter 2021 Financial Results
Increase of 40% in third quarter revenue to $20.0 million over the corresponding period in 2020Increase of 112% in year-to-date revenue to $58.6 million over the corresponding period in 2020 Raising 2021 full year revenue guidance to $77-79 millionAddition of 61 new customer accounts expands and diversifies customer baseExpansion of leadership team with senior life science executivesSubstantial cash and investments of $676 million enabling continued growth acceleration initiatives Company to hos
- GlobeNewswire
SomaLogic to Present at the Stifel 2021 Virtual Healthcare Conference
NEW YORK and BOULDER, Colo., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Stifel 2021 Virtual Healthcare Conference. SomaLogic’s management is scheduled to participate in a fireside chat on Wednesday, November 17, 2021 at 11:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s webs
- GlobeNewswire
SomaLogic announces strategic collaboration with University Hospitals Cleveland Medical Center to treat diabetic patients at high risk of cardiovascular disease
BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with one of the nation’s leading academic medical centers, University Hospitals Cleveland Medical Center, where they will evaluate the impact of the company’s SomaSignal™ tests on the medical management of diabetic patients who are at a higher risk of cardiovascular disease. As part of the collaboration, University Hospitals (UH) Cle
